Anupam Rasayan India Ltd

Anupam Rasayan India Ltd has announced the closure of its trading window from Wednesday, July 01, 2026. This closure will remain in effect until 48 hours after the declaration of the company's unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026. The decision aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The announcement aims to prevent insider trading during the sensitive period leading up to and immediately following the financial results disclosure. The company will also host this information on its official website.

Anupam Rasayan India Ltd. has announced the global commercialisation of ETFA (Ethyl trifluoroacetate) production using its proprietary continuous flow chemistry platform. This makes Anupam Rasayan the first company worldwide to achieve this at a commercial scale. ETFA is a key fluorinated building block used in life sciences, pharmaceuticals, and performance materials. The global market for ETFA is estimated at USD 500-600 million. The company highlights that flow chemistry offers advantages in safety, reproducibility, scalability, efficiency, and environmental impact compared to traditional batch processes. This innovation is expected to enhance their position in the specialty chemicals sector.

Anupam Rasayan India Ltd has filed a Draft Letter of Offer with SEBI through its Manager, SBI Capital Markets Limited. This filing relates to a mandatory open offer to acquire up to 2,77,26,848 equity shares of Bliss GVS Pharma Limited at an offer price of ₹299.00 per share. The offer represents 26.00% of the expanded voting share capital of the target company. The open offer is being made in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The Draft Letter of Offer is also available on Anupam Rasayan's website.

Anupam Rasayan India Limited has disclosed that its promoter, Anand Sureshbhai Desai, has created a pledge on 31,50,000 equity shares. This encumbrance was executed in two tranches on May 25, 2026, and May 26, 2026, to secure debt obligations related to the issuance of non-convertible debentures (NCDs) worth ₹160 Crores by the company.

Anupam Rasayan India Ltd has entered into a definitive agreement to acquire a 43.3-48.2% equity stake in Bliss GVS Pharma Limited, followed by an open offer to public shareholders. The acquisition will be financed through ₹300 Crores via Term Loan and a non-controlling, non-voting equity instrument for the balance. This move aims to strengthen Anupam Rasayan's presence across the pharmaceutical value chain, from KSMs to finished dosage formulations, leveraging Bliss GVS Pharma's capabilities in niche dosage forms and international market presence.

Anupam Rasayan India Ltd announced its FY26 financial results, reporting a 65% YoY increase in total revenue to ₹23,836 Mn. EBITDA rose by 32% YoY to ₹5,430 Mn, with a margin of 23%. Profit After Tax increased by 39% YoY to ₹2,222 Mn. Q4FY26 revenue increased by 26% YoY to ₹6,392 Mn, while EBITDA decreased by 6% YoY to ₹1,407 Mn, with a margin of 22%. The company highlighted the acquisition of Jayhawk Fine Chemicals and a definitive agreement to acquire Bliss GVS Pharma.

Anupam Rasayan India Ltd's Board of Directors, in its meeting on May 23, 2026, approved the re-appointment of M/s. K.B. Daliya & Associates as Internal Auditor and M/s. Bhanwarlal Gurjar & Co. as Cost Auditor for the financial year 2026-27. The decision was based on the recommendation of the Audit Committee, as per Regulation 30 of the SEBI Listing Regulations. The board meeting commenced at 12:45 p.m. IST and concluded at 04:55 p.m. IST.

Anupam Rasayan India Ltd plans to acquire up to 74.20% of Bliss GVS Pharma Limited through a share purchase agreement, including an initial 43.30% stake at ₹299 per share, totaling up to ₹1369.51 Cr. The deal includes an option to acquire the remaining shares held by sellers and an open offer to public shareholders for up to 26% of the total paid-up equity share capital at ₹299 per share, aggregating to ₹829.03 Cr. The board has also approved the acquisition of 15% to 100% equity in other entities to facilitate the proposed transaction.

The Board of Directors of Anupam Rasayan India Ltd approved and recommended a final dividend of ₹1.5 per equity share (15% of face value of ₹10 each) for the financial year 2025-26, subject to shareholder approval at the upcoming AGM. The board also approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Other approvals include the reappointment of internal and cost auditors, a proposed acquisition of up to 74.20% of Bliss GVS Pharma Limited, and raising funds via NCDs up to ₹160 Crore.

Anupam Rasayan India Ltd approved audited financial results for the quarter and year ended March 31, 2026. The board recommended a final dividend of ₹1.5 per equity share (15% of face value). They also approved the re-appointment of internal and cost auditors. Furthermore, the company approved the acquisition of up to 74.20% of Bliss GVS Pharma Limited and the issuance of ₹160 Crore in Non-Convertible Debentures on a private placement basis. Vishal Thakkar resigned as Deputy CFO.